The association of statin use after cancer diagnosis with survival in pancreatic cancer patients: a SEER-medicare analysis.
Pancreatic cancer has poor prognosis and existing interventions provide a modest benefit. Statin has anti-cancer properties that might enhance survival in pancreatic cancer patients. We sought to determine whether statin treatment after cancer diagnosis is associated with longer survival in those wi...
Main Authors: | , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2015-01-01
|
Series: | PLoS ONE |
Online Access: | http://europepmc.org/articles/PMC4382214?pdf=render |
id |
doaj-5851cc332ad3470aa7b61685b7528216 |
---|---|
record_format |
Article |
spelling |
doaj-5851cc332ad3470aa7b61685b75282162020-11-25T02:33:55ZengPublic Library of Science (PLoS)PLoS ONE1932-62032015-01-01104e012178310.1371/journal.pone.0121783The association of statin use after cancer diagnosis with survival in pancreatic cancer patients: a SEER-medicare analysis.Christie Y JeonStephen J PandolBechien WuGalen Cook-WiensRoberta A GottliebC Noel Bairey MerzMarc T GoodmanPancreatic cancer has poor prognosis and existing interventions provide a modest benefit. Statin has anti-cancer properties that might enhance survival in pancreatic cancer patients. We sought to determine whether statin treatment after cancer diagnosis is associated with longer survival in those with pancreatic ductal adenocarcinoma (PDAC).We analyzed data on 7813 elderly patients with PDAC using the linked Surveillance, Epidemiology, and End Results (SEER) - Medicare claims files. Information on the type, intensity and duration of statin use after cancer diagnosis was extracted from Medicare Part D. We treated statin as a time-dependent variable in a Cox regression model to determine the association with overall survival adjusting for follow-up, age, sex, race, neighborhood income, stage, grade, tumor size, pancreatectomy, chemotherapy, radiation, obesity, dyslipidemia, diabetes, chronic pancreatitis and chronic obstructive pulmonary disease (COPD).Overall, statin use after cancer diagnosis was not significantly associated with survival when all PDAC patients were considered (HR = 0.94, 95%CI 0.89, 1.01). However, statin use after cancer diagnosis was associated with a 21% reduced hazard of death (Hazard ratio = 0.79, 95% confidence interval (CI) 0.67, 0.93) in those with grade I or II PDAC and to a similar extent in those who had undergone a pancreatectomy, in those with chronic pancreatitis and in those who had not been treated with statin prior to cancer diagnosis.We found that statin treatment after cancer diagnosis is associated with enhanced survival in patients with low-grade, resectable PDAC.http://europepmc.org/articles/PMC4382214?pdf=render |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Christie Y Jeon Stephen J Pandol Bechien Wu Galen Cook-Wiens Roberta A Gottlieb C Noel Bairey Merz Marc T Goodman |
spellingShingle |
Christie Y Jeon Stephen J Pandol Bechien Wu Galen Cook-Wiens Roberta A Gottlieb C Noel Bairey Merz Marc T Goodman The association of statin use after cancer diagnosis with survival in pancreatic cancer patients: a SEER-medicare analysis. PLoS ONE |
author_facet |
Christie Y Jeon Stephen J Pandol Bechien Wu Galen Cook-Wiens Roberta A Gottlieb C Noel Bairey Merz Marc T Goodman |
author_sort |
Christie Y Jeon |
title |
The association of statin use after cancer diagnosis with survival in pancreatic cancer patients: a SEER-medicare analysis. |
title_short |
The association of statin use after cancer diagnosis with survival in pancreatic cancer patients: a SEER-medicare analysis. |
title_full |
The association of statin use after cancer diagnosis with survival in pancreatic cancer patients: a SEER-medicare analysis. |
title_fullStr |
The association of statin use after cancer diagnosis with survival in pancreatic cancer patients: a SEER-medicare analysis. |
title_full_unstemmed |
The association of statin use after cancer diagnosis with survival in pancreatic cancer patients: a SEER-medicare analysis. |
title_sort |
association of statin use after cancer diagnosis with survival in pancreatic cancer patients: a seer-medicare analysis. |
publisher |
Public Library of Science (PLoS) |
series |
PLoS ONE |
issn |
1932-6203 |
publishDate |
2015-01-01 |
description |
Pancreatic cancer has poor prognosis and existing interventions provide a modest benefit. Statin has anti-cancer properties that might enhance survival in pancreatic cancer patients. We sought to determine whether statin treatment after cancer diagnosis is associated with longer survival in those with pancreatic ductal adenocarcinoma (PDAC).We analyzed data on 7813 elderly patients with PDAC using the linked Surveillance, Epidemiology, and End Results (SEER) - Medicare claims files. Information on the type, intensity and duration of statin use after cancer diagnosis was extracted from Medicare Part D. We treated statin as a time-dependent variable in a Cox regression model to determine the association with overall survival adjusting for follow-up, age, sex, race, neighborhood income, stage, grade, tumor size, pancreatectomy, chemotherapy, radiation, obesity, dyslipidemia, diabetes, chronic pancreatitis and chronic obstructive pulmonary disease (COPD).Overall, statin use after cancer diagnosis was not significantly associated with survival when all PDAC patients were considered (HR = 0.94, 95%CI 0.89, 1.01). However, statin use after cancer diagnosis was associated with a 21% reduced hazard of death (Hazard ratio = 0.79, 95% confidence interval (CI) 0.67, 0.93) in those with grade I or II PDAC and to a similar extent in those who had undergone a pancreatectomy, in those with chronic pancreatitis and in those who had not been treated with statin prior to cancer diagnosis.We found that statin treatment after cancer diagnosis is associated with enhanced survival in patients with low-grade, resectable PDAC. |
url |
http://europepmc.org/articles/PMC4382214?pdf=render |
work_keys_str_mv |
AT christieyjeon theassociationofstatinuseaftercancerdiagnosiswithsurvivalinpancreaticcancerpatientsaseermedicareanalysis AT stephenjpandol theassociationofstatinuseaftercancerdiagnosiswithsurvivalinpancreaticcancerpatientsaseermedicareanalysis AT bechienwu theassociationofstatinuseaftercancerdiagnosiswithsurvivalinpancreaticcancerpatientsaseermedicareanalysis AT galencookwiens theassociationofstatinuseaftercancerdiagnosiswithsurvivalinpancreaticcancerpatientsaseermedicareanalysis AT robertaagottlieb theassociationofstatinuseaftercancerdiagnosiswithsurvivalinpancreaticcancerpatientsaseermedicareanalysis AT cnoelbaireymerz theassociationofstatinuseaftercancerdiagnosiswithsurvivalinpancreaticcancerpatientsaseermedicareanalysis AT marctgoodman theassociationofstatinuseaftercancerdiagnosiswithsurvivalinpancreaticcancerpatientsaseermedicareanalysis AT christieyjeon associationofstatinuseaftercancerdiagnosiswithsurvivalinpancreaticcancerpatientsaseermedicareanalysis AT stephenjpandol associationofstatinuseaftercancerdiagnosiswithsurvivalinpancreaticcancerpatientsaseermedicareanalysis AT bechienwu associationofstatinuseaftercancerdiagnosiswithsurvivalinpancreaticcancerpatientsaseermedicareanalysis AT galencookwiens associationofstatinuseaftercancerdiagnosiswithsurvivalinpancreaticcancerpatientsaseermedicareanalysis AT robertaagottlieb associationofstatinuseaftercancerdiagnosiswithsurvivalinpancreaticcancerpatientsaseermedicareanalysis AT cnoelbaireymerz associationofstatinuseaftercancerdiagnosiswithsurvivalinpancreaticcancerpatientsaseermedicareanalysis AT marctgoodman associationofstatinuseaftercancerdiagnosiswithsurvivalinpancreaticcancerpatientsaseermedicareanalysis |
_version_ |
1724811563983962112 |